Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.…
Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
Ascentage Pharma Group Internat (NASDAQ: AAPG) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 828 employees.
The shares were at 11.97 USD on 20 November 2026, down 62.8% over 52 weeks. Its 52-week range is 11.97 USD to 33.09 USD, and it trades at the bottom of that range.
Its market capitalisation is 1.12B USD.
Ascentage Pharma Group Internat reports return on equity of -93.8%, an operating margin of -219.5% and revenue up 29.3% year over year.
Its debt exceeds its cash by 198.99M CNY, a debt-to-equity ratio of 1.49. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 10 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 44.50 USD is 271.8% above the current price. The next earnings report is expected on 25 March 2027.